Advancing Insights Into Diabetic Eye Disease: 5th Annual American Society of Retina Specialists Presidents’ Young Investigator Award Lecture

Abstract

Diabetes and its complications are an emerging public health crisis. Since vision changes can be irreversible in diabetic retinopathy (DR), early detection, recognition of prognostics, and treatment are important to prevent vision loss from DR. At the 2018 American Society of Retina Specialists (ASRS) Annual Meeting, Dr Rishi P. Singh was honored to receive the fifth annual ASRS Presidents’ Young Investigator Award. This article summarizes many advancements in diabetic eye disease that we have witnessed recently covering the concepts of DR, disease pathogenesis, new imaging modalities, and improving treatment outcomes.

Keywords

diabetic retinopathy macular edema diabetic retinopathy screening

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed June 25, 2019.

Zhang

Saaddine

Chou

et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304(6):649–656. doi:10.1001/jama.2010.1111

Brownlee

. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. doi:10.2337/diabetes.54.6.1615

Yau

Rogers

Kawasaki

et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909

Melancia

Vicente

Cunha

Abegão Pinto

Ferreira

. Diabetic choroidopathy: a review of the current literature. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1453–1461. doi:10.1007/s00417-016-3360-8

Hua

Liu

Wang

Chen

. Imaging evidence of diabetic choroidopathy in vivo: angiographic pathoanatomy and choroidal-enhanced depth imaging. PloS One. 2013;8(12):1–5. doi:10.1371/journal.pone.0083494

Agemy

Scripsema

Shah

et al. Retinal vascular perfusion density mapping using optical coherence tomography angiography in normals and diabetic retinopathy patients. Retina. 2015;35(11):2353–2363. doi:10.1097/IAE.0000000000000862

Mrejen

Spaide

. Optical coherence tomography: imaging of the choroid and beyond. Surv Ophthalmol. 2013;58(5):387–429. doi:10.1016/j.survophthal.2012.12.001

Conti

Qin

Rodrigues

et al. Choriocapillaris and retinal vascular plexus density of diabetic eyes using split-spectrum amplitude decorrelation spectral-domain optical coherence tomography angiography. Br J Ophthalmol. 2019;103(4):452–456. doi:10.1136/bjophthalmol-2018-311903

10.

Zhu

Zhang

Kong

Wang

Zhang

. Effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes mellitus. Int J Ophthalmol. 2013;6(2):141–145. doi:10.3980/j.issn.2222-3959.2013.02.06

11.

American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(suppl 1):S11–S66. doi:10.2337/dc13-S011

12.

Wentworth

Playfair

Laurie

et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(7):545–552. doi:10.1016/S2213-8587(14)70066-X

13.

The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA_1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44(8):968–983. doi:10.2337/diab.44.8.968

14.

Feldman-Billard

Larger

Massin

; Standards for Screening and Surveillance of Ocular Complications in People With Diabetes SFD Study Group. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2017;44(1):4–14. doi:10.1016/j.diabet.2017.10.014

15.

Kondo

Vicent

Suzuma

et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest. 2003;111(12):1835–1842. doi:10.1172/JCI200317455

16.

Poulaki

Joussen

Mitsiades

Iliaki

Adamis

. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol. 2004;165(2):457–469. doi:10.1016/S0002-9440(10)63311-1

17.

Brownlee

. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820. doi:10.1038/414813a

18.

Treins

Giorgetti-Peraldi

Murdaca

Semenza

Van Obberghen

. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002;277(31):27975–27981. doi:10.1074/jbc.M204152200

19.

Thangarajah

Yao

Chang

et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009;106(32):13505–13510. doi:10.1073/pnas.93.23.12969

20.

ADVANCE Collaborative Group; Patel

MacMahon

et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi:10.1056/NEJMoa0802987

21.

Johnson

Blackhurst

Latham

et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013;216(4):545–556; discussion 556-558. doi:10.1016/j.jamcollsurg.2012.12.019

22.

Kashyap

Bhatt

Schauer

; STAMPEDE Investigators. Bariatric surgery vs. advanced practice medical management in the treatment of type 2 diabetes mellitus: rationale and design of the Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently Trial (STAMPEDE). Diabetes Obes Metab. 2010;12(5):452–454. doi:10.1111/j.1463-1326.2009.01172.x

23.

Schauer

Bhatt

Kirwan

et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–651. doi:10.1056/NEJMoa1600869

24.

Singh

Gans

Kashyap

et al. Effect of bariatric surgery versus intensive medical management on diabetic ophthalmic outcomes. Diabetes Care. 2015;38(3):e32–e33. doi:10.2337/dc14-2035

25.

Early Treatment Diabetic Retinopathy Study design and baseline characteristics. ETDRS report number 7. Ophthalmology. 1990;98(5 suppl):741–756. doi:10.1016/S0161-6420(13)38009-9

26.

Mitchell

Bandello

Schmidt-Erfurth

et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625. doi:10.1016/j.ophtha.2011.01.031

27.

Brown

Nguyen

Marcus

et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022. doi:10.1016/j.ophtha.2013.02.034

28.

Warid Al-Laftah

Elshafie

Alhashimi

Pai

Farouq

. Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema. Saudi J Ophthalmol. 2010;24(4):133–138. doi:10.1016/j.sjopt.2010.05.001

29.

Gross

Glassman

Liu

et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–1148. doi:10.1001/jamaophthalmol.2018.3255

30.

Bressler

Qin

Beck

et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153–1161. doi:10.1001/archophthalmol.2012.1107

31.

Matsuda

Tam

Singh

et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2):166–170. doi:10.1016/j.jdiacomp.2013.11.009

32.

Bansal

Khurana

Wieland

Wang

Van Everen

Tuomi

. Influence of glycosylated hemoglobin on the efficacy of ranibizumab for diabetic macular edema: a post hoc analysis of the RIDE/RISE trials. Ophthalmology. 2015;122(8):1573–1579. doi:10.1016/j.ophtha.2015.04.029

33.

Singh

Habbu

Ehlers

Lansang

Hill

Stoilov

. The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmology. 2016;123(7):1581–1587. doi:10.1016/j.ophtha.2016.03.038

34.

Dhoot

Baker

Saroj

et al. Baseline factors affecting changes in diabetic retinopathy severity scale score after intravitreal aflibercept or laser for diabetic macular edema: post hoc analyses from VISTA and VIVID. Ophthalmology. 2018;125(1):51–56. doi:10.1016/j.ophtha.2017.06.029

35.

Gulkilik

Kocabora

Taskapili

Engin

. Cystoid macular edema after phacoemulsification: risk factors and effect on visual acuity. Can J Ophthalmol. 2006;41(6):699–703. doi:10.3129/i06-062

36.

Kim

Equi

Bressler

. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114(5):881–889. doi:10.1016/j.ophtha.2006.08.053

37.

Chu

Johnston

Buscombe

et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316–323. doi:10.1016/j.ophtha.2015.10.001

38.

Schoenberger

Kim

. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013;2013:281981. doi:10.1155/2013/281981

39.

Russo

Costagliola

Delcassi

et al. Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm. 2013;2013:476525. doi:10.1155/2013/476525

40.

Kim

Flach

Jampol

. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108–133. doi:10.1016/j.survophthal.2009.07.005

41.

Singh

Alpern

Jaffe

et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259–1269. doi:10.2147/OPTH.S31902

42.

Pollack

Staurenghi

Sager

Mukesh

Reiser

Singh

. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol. 2017;101(4):423–427. doi:10.1136/bjophthalmol-2016-308617

43.

Singh

Lehmann

Martel

et al. Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies. Ophthalmology. 2017;124(6):776–785. doi:10.1016/j.ophtha.2017.01.036

44.

Diabetic Retinopathy Clinical Research Network, Wells

Glassman

et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi:10.1056/NEJMoa1414264.Aflibercept

45.

Awh

. LADDER trial of the port delivery system for ranibizumab: preliminary study results. Paper presented at: 36th Annual Meeting of the American Society of Retina Specialists; July 20–25, 2018; Vancouver, British Columbia, Canada.

46.

ClinicalTrials.gov. Novartis Investigative. Identifier: NCT03481634 Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL). https://clinicaltrials.gov/ct2/show/NCT03481634?id=NCT0348163. Published March 29, 2018. Updated March 1, 2019. Accessed June 25, 2019.

47.

ClinicalTrials.gov. Jaeb Center for Health Research. Identifier: NCT03866473 A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema (AE). https://clinicaltrials.gov/ct2/show/NCT03866473/. Published March 7, 2019. Updated May 23, 2019. Accessed June 25, 2019.